# Berry & Associates (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/berry-and-associates-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 110 |
| Citations | 116,396 |
| City | Dexter |
| Country | US |
| Description | Berry & Associates (United States) is a research organisation in Dexter, US. OpenAlex records 773 works and 116,396 citations for it. 166 researchers list it as their most recent affiliation. |
| Homepage | https://www.georgiabankruptcyfiling.com/ |
| OpenAlex ID | https://openalex.org/I4210100030 |
| Region | Michigan |
| Researchers | 166 |
| ROR ID | https://ror.org/01a5r1q21 |
| Type | company |
| Works | 773 |

## University papers

Showing 12 of 19.

- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or/)
- [Revision of the American Joint Committee on Cancer Staging System for Breast Cancer](https://scholariq.org/papers/revision-of-the-american-joint-committee-on-cancer-staging-system-for-breast/)
- [Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-70-years-of-age/)
- [Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)](https://scholariq.org/papers/impact-of-the-addition-of-carboplatin-and-or-bevacizumab-to-neoadjuvant-once-per/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative](https://scholariq.org/papers/personalized-medicine-in-a-phase-i-clinical-trials-program-the-md-anderson/)
- [BRCAPRO Validation, Sensitivity of Genetic Testing of <i>BRCA1/BRCA2</i>, and Prevalence of Other Breast Cancer Susceptibility Genes](https://scholariq.org/papers/brcapro-validation-sensitivity-of-genetic-testing-of-i-brca1-brca2-i-and/)
- [Addressing overdiagnosis and overtreatment in cancer: a prescription for change](https://scholariq.org/papers/addressing-overdiagnosis-and-overtreatment-in-cancer-a-prescription-for-change/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)

## University top topics

Showing 8 of 25.

- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Advanced Causal Inference Techniques](https://scholariq.org/topics/advanced-causal-inference-techniques/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Meta-analysis and systematic reviews](https://scholariq.org/topics/meta-analysis-and-systematic-reviews/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Statistical Methods and Bayesian Inference](https://scholariq.org/topics/statistical-methods-and-bayesian-inference/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.